Disclosures: Fung reports consultant roles with Amgen and Sanofi. Tell us what you think about Healio. Login Register My Saved. In the Journals Perspective. January 23, Please provide your email address to receive an email when new articles are posted on this topic. Receive an email when new articles are posted on this topic. The American Society of Clinical Oncology released updates to their guidelines for thromboprophylaxis in patients with cancer. Second-line treatment strategies for severe aplastic anemia include stem cell transplant, immunosuppressive therapy, and thrombopoietin mimetics.
The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies. In a review article, researchers discussed how to maximize treatment efficacy while minimizing adverse effects for patients with mantle cell lymphoma. Lack of resources and poor awareness of thalassemia can make it difficult for patients with beta thalassemia to receive necessary blood transfusions. Oncology nurses discuss the importance of ongoing education on the treatments, symptoms, and available information on MPNs for patients, and oncology nurses.
New studies in morbidly obese patients suggest that direct oral anticoagulants may be a safe and efficacious treatment option for thromboembolism and atrial fibrillation. Researchers highlighted the current status of diagnostic strategies and laboratory screening tests for von Willebrand disease. By Christina Bennett, MS.
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported. Both autologous and allogeneic stem cell transplantation have shown benefits in patients with relapsed follicular lymphoma, but long-term data are lacking. Combining caplacizumab with therapeutic plasma exchange could decrease hospital stays and treatment costs in the long term. In addition to current obinutuzumab- and rituximab-based treatment regimens, several novel agents have received approval for follicular lymphoma treatment.
Current treatment strategies for immune thrombocytopenic purpura are centered on immunomodulation and decreasing platelet destruction. Many clinical and ethical factors influence whether preemptive transplant would be beneficial for patients genetically predisposed to acute myeloid leukemia. Though lymphoproliferative diseases during pregnancy can lead to complications, a host of treatment options exists.
Treatment strategies for children with hemophilia who have inhibitors should involve eradicating the inhibitor and managing bleeding. In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma. Therapeutic plasma exchange could become an effective mainstay of treatment for immune-mediated thrombotic thrombocytopenic purpura.
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia. With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma. One important endpoint to be measured in future studies is MRD negativity in standard or high-risk disease, since it is a significant predictor of PFS, OS, and potential cure in a fraction of patients To possibly achieve MRD negativity at even lower cutoff, daratumumab will likely need to be added.
Finally, even though first line for multiple myeloma treatment, the use of transplantation remains limited by accessibility and availability which differs across nations and is limited in developing countries. Harousseau, J. Autologous hematopoietic stem-cell transplantation for multiple myeloma. McElwain, T. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2 , — Barlogie, B. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67 , — High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma.
Blood 70 , — Mohty, M.
Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. Haematologica 99 , — Attal, M. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. Child, J. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
- One Legacy of Paul F. Brandwein: Creating Scientists: 2 (Classics in Science Education).
- Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
- Behavior Analysis and Interviewing Techniques (BAIT).
- Multiple Myeloma bone Marrow Angiogenesis — Italian Ministry of Health?
Lenalidomide, Bortezomib, and Dexamethasone with transplantation for myeloma. Koreth, J. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Blood Marrow Transplant. Jr, Anaissie, E. Making progress in treating multiple myeloma with total therapies: issue of complete remission and more. Leukemia 22 , — Paiva, B.
Current status of autologous stem cell transplantation for multiple myeloma
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. Ladetto, M. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
- Given Pause.
- The Bird of Heaven;
- Federal Practitioner - Current Trends in MM Current Trends in Multiple Myeloma!
- Strategies for the Treatment of Multiple Myeloma in 2013: Moving Toward the Cure.
Cavo, M. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet , — Moreau, P.
Multiple Myeloma - A New Era of Treatment Strategies
Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. Facon, T.
click here Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma IFM : a randomised trial. Badros, A. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years.
Judith Neukirchen, P. Favourable outcome of elderly patients with multiple myeloma treated with tandem melphalan high-dose therapy, autologous stem cell transplantation and novel agents—a single center experience. Blood , Palumbo, A. Dose-intensive melphalan with stem cell support MEL is superior to standard treatment in elderly myeloma patients.
Blood 94 , — Gay, F. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood , — Straka, C. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.
Haematologica , — Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Tosi, P.